TSVT
2025-03-31 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenues | - | 13,534 | 8,967 | |
| Change in fair value of contingent consideration | - | - | -685 | |
| Selling, general and administrative | - | 12,884 | 9,857 | |
| Research and development | - | 8,320 | 16,013 | |
| Restructuring expenses | - | 503 | 7,398 | |
| Cost of manufacturing for commercial collaboration | - | 5,768 | 3,453 | |
| Total operating expenses | - | 27,475 | 36,036 | |
| Loss from operations | - | -9,392 | 24,979 | |
| Other comprehensive income (loss), net of tax benefit (expense) of 0.0million and 0.0million for the three and nine months ended september 30, 2024 and 2023, respectively | - | 541 | 100 | |
| Loss on assets held for sale to regeneron | - | - | 47,987 | |
| Other income, net | - | 1,153 | 1,434 | |
| Interest income, net | - | 2,855 | 2,527 | |
| Loss before income taxes | - | -9,933 | 24,879 | |
| Net loss | - | -9,933 | 24,879 | |
| Comprehensive loss | - | -9,392 | 24,979 | |
| Basic eps | 0.01 | -0.19 | 0.48 | |
| Diluted eps | 0.01 | -0.19 | 0.45 | |
| Basic average shares | 53,055,000 | 52,263,000 | 52,186,000 | |
| Diluted average shares | 53,433,000 | 52,263,000 | 55,011,000 | |